135 related articles for article (PubMed ID: 22648001)
1. Intact fibroblast growth factor 23 and fragments in plasma from Gambian children.
Braithwaite V; Bruggraber SF; Prentice A
Osteoporos Int; 2013 Mar; 24(3):1121-4. PubMed ID: 22648001
[TBL] [Abstract][Full Text] [Related]
2. FGF23 is elevated in Gambian children with rickets.
Prentice A; Ceesay M; Nigdikar S; Allen SJ; Pettifor JM
Bone; 2008 Apr; 42(4):788-97. PubMed ID: 18234575
[TBL] [Abstract][Full Text] [Related]
3. Iron status and fibroblast growth factor-23 in Gambian children.
Braithwaite V; Jarjou LM; Goldberg GR; Prentice A
Bone; 2012 Jun; 50(6):1351-6. PubMed ID: 22465847
[TBL] [Abstract][Full Text] [Related]
4. Follow-up study of Gambian children with rickets-like bone deformities and elevated plasma FGF23: possible aetiological factors.
Braithwaite V; Jarjou LM; Goldberg GR; Jones H; Pettifor JM; Prentice A
Bone; 2012 Jan; 50(1):218-25. PubMed ID: 22023931
[TBL] [Abstract][Full Text] [Related]
5. Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children.
Braithwaite V; Jones KS; Assar S; Schoenmakers I; Prentice A
Endocr Connect; 2014; 3(1):1-10. PubMed ID: 24258305
[TBL] [Abstract][Full Text] [Related]
6. Method-specific differences in plasma fibroblast growth factor 23 measurement using four commercial ELISAs.
Smith ER; McMahon LP; Holt SG
Clin Chem Lab Med; 2013 Oct; 51(10):1971-81. PubMed ID: 23729624
[TBL] [Abstract][Full Text] [Related]
7. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type.
El-Maouche D; Dumitrescu CE; Andreopoulou P; Gafni RI; Brillante BA; Bhattacharyya N; Fedarko NS; Collins MT
Osteoporos Int; 2016 Jul; 27(7):2345-2353. PubMed ID: 26928188
[TBL] [Abstract][Full Text] [Related]
8. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
9. The effect of burosumab on intact and C-terminal FGF23 measurements.
Ashrafzadeh-Kian SL; Ito N; Srivastava T; Garg U; Kato H; Algeciras-Schimnich A; Bornhorst JA
Clin Endocrinol (Oxf); 2023 Aug; 99(2):152-157. PubMed ID: 36263608
[TBL] [Abstract][Full Text] [Related]
10. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.
Shimada T; Urakawa I; Isakova T; Yamazaki Y; Epstein M; Wesseling-Perry K; Wolf M; Salusky IB; Jüppner H
J Clin Endocrinol Metab; 2010 Feb; 95(2):578-85. PubMed ID: 19965919
[TBL] [Abstract][Full Text] [Related]
11. Iron and fibroblast growth factor 23 in X-linked hypophosphatemia.
Imel EA; Gray AK; Padgett LR; Econs MJ
Bone; 2014 Mar; 60():87-92. PubMed ID: 24325979
[TBL] [Abstract][Full Text] [Related]
12. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
Imel EA; Peacock M; Gray AK; Padgett LR; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2011 Nov; 96(11):3541-9. PubMed ID: 21880793
[TBL] [Abstract][Full Text] [Related]
13. [Bone and bone related biochemical examinations. Hormone and hormone related substances. The measurement of circulating fibroblast growth factor 23 (FGF-23)].
Kobayashi K; Imanishi Y
Clin Calcium; 2006 Jun; 16(6):935-39. PubMed ID: 16751688
[TBL] [Abstract][Full Text] [Related]
14. Biological variability of plasma intact and C-terminal FGF23 measurements.
Smith ER; Cai MM; McMahon LP; Holt SG
J Clin Endocrinol Metab; 2012 Sep; 97(9):3357-65. PubMed ID: 22689697
[TBL] [Abstract][Full Text] [Related]
15. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays.
Durham BH; Joseph F; Bailey LM; Fraser WD
Ann Clin Biochem; 2007 Sep; 44(Pt 5):463-6. PubMed ID: 17761032
[TBL] [Abstract][Full Text] [Related]
16. C-Terminal Fibroblast Growth Factor-23 Levels in Non-Nutritional Hypophosphatemic Rickets.
Bharati J; Bhatia D; Khandelwal P; Gupta N; Sinha A; Khadgawat R; Hari P; Bagga A
Indian J Pediatr; 2019 Jun; 86(6):555-557. PubMed ID: 30835073
[TBL] [Abstract][Full Text] [Related]
17. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
18. The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism.
Braithwaite VS; Prentice A; Darboe MK; Prentice AM; Moore SE
Bone; 2016 Feb; 83():1-8. PubMed ID: 26453792
[TBL] [Abstract][Full Text] [Related]
19. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
Araya K; Fukumoto S; Backenroth R; Takeuchi Y; Nakayama K; Ito N; Yoshii N; Yamazaki Y; Yamashita T; Silver J; Igarashi T; Fujita T
J Clin Endocrinol Metab; 2005 Oct; 90(10):5523-7. PubMed ID: 16030159
[TBL] [Abstract][Full Text] [Related]
20. Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels.
Knab VM; Corbin B; Andrukhova O; Hum JM; Ni P; Rabadi S; Maeda A; White KE; Erben RG; Jüppner H; Christov M
Endocrinology; 2017 May; 158(5):1130-1139. PubMed ID: 28324013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
